Based in San Antonio, Texas, OncoVista was incorporated in 2004 and utilizes state-of-the-art drug discovery technologies, innovative clinical development and registration strategies as well as emerging technologies to bring to market new, safe and highly effective anti-cancer drugs.

2004

Company founded based on two key platform technologies

2005

Acquired majority share in AdnaGen AG

2006

Merged with Aengus Pharmaceuticals
Acquired a Phase I/II clinical candidate

2007

Became publicly-traded
In-licensed a Phase II clinical candidate

2008

Initiated Phase I/II clinical trial for leukemia at two US sites
Launched CLIA lab capability in the US
Increase sales of AdnaGen diagnostic kits in Europe
Increased ownership of AdnaGen AG to more than 95%

2010

Entered into a Stock Purchase Agreement with a buyer whereby the Company sold all of its AdnaGen AG majority holding representing approximately 78% of the total issued and outstanding shares.